Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889588 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL16452917 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL7778087 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL5612699 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL10665563 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9234559 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9716658 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL31390220 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9716661 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL6562811 | 0.89 | CHRNB2 (0.59) | LMNATDP1PSMB5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | claimed |
| US-10968172-B2 | USP30 inhibitors | MITOBRIDGE, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131121-A1 | USP30 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| WO-2018213150-A1 | USP30 INHIBITORS | MITOBRIDGE, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-20150045435-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | UNIV INDIANA RES & TECH CORP (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045435-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | UNIV INDIANA RES & TECH CORP (US) | 2015-02-12 | — | — | US | disclosed |
| US-20090076304-A1 | METHODS FOR PRODUCING CARBOXYLIC ACID CHLORIDE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968172-B2 | USP30 inhibitors | USP30, UBQLN1, UBQLN2 | LMNA 2538/4885TDP1 454/4885PSMB5 30/4885 |
| US-20150045435-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | SLC5A1, SLC5A2, GPR119 | LMNA 1730/4885TDP1 4062/4885PSMB5 2879/4885 |
| US-20090076304-A1 | METHODS FOR PRODUCING CARBOXYLIC ACID CHLORIDE COMPOUNDS | DDC, CPS1, PCCA | LMNA 4384/4885TDP1 4083/4885PSMB5 2733/4885 |
| US-20200131121-A1 | USP30 INHIBITORS | USP30, UBQLN1, UBQLN2 | LMNA 2538/4885TDP1 454/4885PSMB5 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.